TD Cowen Maintains Novartis AG(NVS.US) With Hold Rating, Maintains Target Price $180Market news · 9 Sep 2026
Setback for the second time in a week! Novartis (NVS.US) sees its blockbuster heart disease drug fail in Phase III trials, causing a sharp drop in share price; Amgen (AMGN.US) suffers collateral damage.Zhitong Finance · 7 Sep 2026
BofA Securities Maintains Novartis AG(NVS.US) With Buy Rating, Raises Target Price to $185.56Market news · 7 Sep 2026
Strong sales of innovative drugs offset the impact from generics! Novartis AG (NVS.US) Q2 results beat expectations, signaling a return to growth trajectory.Zhitong Finance · 21 Jul 2026
Argus Research Initiates Novartis AG(NVS.US) With Buy Rating, Announces Target Price $160Market news · 6 Jun 2026
TD Cowen Maintains Novartis AG(NVS.US) With Hold Rating, Raises Target Price to $180Market news · 12 Jun 2026
BofA Securities Maintains Novartis AG(NVS.US) With Buy Rating, Raises Target Price to $177.37Market news · 11 Jun 2026
SAAG CONSOLIDATED (M): Britac Berhad Disposal of 350,000 shares of HK$1.00 each representing 70% of the total issued and paid up share capital of Britac (China) Limited by Britac-Saag (S) Pte Ltd, a wholly owned subsidiary of Britac Berhad to NVS Invest &Bursa Malaysia · 22 Apr 2026
SAAG CONSOLIDATED (M): Britac Berhad ("Britac") - Disposal of 350,000 shares of HK$1.00 each representing 70% of the total issued and paid up share capital of Britac (China) Limited by Britac-Saag (S) Pte Ltd, a wholly owned subsidiary of Britac to NVSBursa Malaysia · 17 Apr 2026